¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Expert Rev Anti Infect Ther"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-Sp autoantibody
    Ç×-Sp ÀÚ°¡Ç×ü
  • anti-antidote
    Ç×ÇØµ¶¾à.
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • anti-glomerular,basement menbrane nephritis
    Ç׻籸ü±âÀú¸·½Å¿°(ù÷Þêϳô÷Ðñî¼Ø¯ãìæú)
  • anti-i autoantibody
    Ç×-I ÀÚ°¡Ç×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • anti-immune body
    Ç׸鿪ü.
  • anti-infective
    Ç×°¨¿°¼º, Ç×°¨¿°¾à.
  • anti-infective
    1. Ç×°¨¿°¼º. 2. Ç×°¨¿°¾à.
  • anti-inflammatory
    Ç׿°Áõ¼º(ù÷æúñøàõ)ÀÇ.
  • anti-inflammatory
    Ç׿°(Áõ)¼º
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-Sp autoantibody
    Ç×-Sp ÀÚ°¡Ç×ü
  • anti-antidote
    Ç×ÇØµ¶¾à.
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • anti-glomerular,basement menbrane nephritis
    Ç׻籸ü±âÀú¸·½Å¿°(ù÷Þêϳô÷Ðñî¼Ø¯ãìæú)
  • anti-i autoantibody
    Ç×-I ÀÚ°¡Ç×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • anti-immune body
    Ç׸鿪ü.
  • anti-infective
    Ç×°¨¿°¼º, Ç×°¨¿°¾à.
  • anti-infective
    1. Ç×°¨¿°¼º. 2. Ç×°¨¿°¾à.
  • anti-inflammatory
    Ç׿°Áõ¼º(ù÷æúñøàõ)ÀÇ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MedIndEx medical indexing expert
MEDSTATS Medical Statistics Expert System
QFES Quality Feedback Expert System
AB, Ab   1) Anti-body; Ç×ü
  2) Anti-Biotics; Ç×»ýÁ¦
Anti-ENA Anti-Extractable Nuclear Antigens
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
REV Reticuloendotheliosis virus
REV-T Reticuloendotheliosis virus strain T
RRE Rev Responsive Element
REV reverse phase evaporation
anti-B4-bR Anti-B-blocked ricin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • F1 anti-parental cytotoxicity
    F1 Ç× ¾çÄ£ ¼¼Æ÷ »óÇØ, F1 Ç× ¾çÄ£ ¼¼Æ÷ µ¶¼º
    in vivo¿¡¼­ F
  • F2 anti-parental cytotoxicity
    F2 Ç× ¾çÄ£ ¼¼Æ÷ »óÇØ
    in vitro¿¡¼­ F
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
anti-basement membrane glomerulonephritis Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome.
(05 Mar 2000)
anti-basement membrane nephritis Glomerulonephritis produced by autologous or heterologous antibodies to the glomerular capillary basement membranes, the latter known as anti-kidney serum nephritis.
(05 Mar 2000)
anti-black-tongue factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
antibodies, anti-idiotypic Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
(12 Dec 1998)
anti-coagulant agents Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels.
(12 Dec 1998)
anti-D immunoglobulin rHo(D) immune globulin
anti-DNAse B This is a serologic blood test used to detect antibodies against antideoxyribonuclease B (anti-DNAse B), an antigen that is produced by group A streptococci. This test is used to document a previous streptococcal infection in those who are suspected of having post-streptococcal disease (for example acute glomerulonephritis, rheumatic fever). A normal value is a negative assay. In adults this is less than 85 Todd units /ml. In school-age children this is less than 170 Todd units/ml. In pre-schoolers this is less than 60 Todd units/ml. Anywhere from 70 to 80% of people with rheumatic fever or post-streptococcal acute glomerulonephritis will have elevated anti-DNAse B levels. The test is performed on a venipuncture specimen.
(27 Sep 1997)
anti-dyskinesia agents Drugs used in the treatment of movement disorders. most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the tardive dyskinesias.
(12 Dec 1998)
anti-G In the strict sense, a term that means "antigravity" but, as commonly used, an adjectival term that implies protection against the effects of gravity (e.g., anti-G suit).
(05 Mar 2000)
anti-glomerular basement membrane disease Glomerulonephritis, usually of a generalised proliferative crescent-forming histologic type with a rapidly progressive course, marked by circulating anti-gbm antibodies and linear deposits of immunoglobulin and complement along the glomerular basement membrane. When associated with pulmonary haemorrhage the condition is called goodpasture syndrome.
(12 Dec 1998)
anti-G suit A garment with bladders that expand to apply external pressure to the abdomen and lower extremities during positive G manoeuvres in flight or on a human centrifuge; the anti-G suit is worn to prevent the pooling of blood and serves to increase the wearer's ability to withstand exposure to higher G forces.
(05 Mar 2000)
anti-HBc Antibody to the hepatitis B core antigen (HBcAg).
(05 Mar 2000)
anti-HBe Antibody to the hepatitis B e antigen (HBeAg).
(05 Mar 2000)
anti-HBs Antibody to the hepatitis B surface antigen (HBsAg).
(05 Mar 2000)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • rev.
    revenue;reverse(d);review(ed);revise(d);revision;revolution;revolving
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á